drugset

drugset / Trial / NCT00882882

To Demonstrate the Relative Bioavailability of Metformin HCL 500 mg Extended Release (XR) Tablets Under Fasting Conditions

NCT00882882 ↗

Phase 1 Completed 16 enrolled Sandoz

RandomizedCrossoverOpen-labelTreatment

Summary

To demonstrate the relative bioavailability of Metformin HCl 500 mg XR tablets under fasting conditions.

Timeline

Start: 2001-06
Primary completion: 2001-06
Completion: 2001-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Metformin	Small molecule	500 mg	—

Indications